CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 63 filers reported holding CYTOMX THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $9,400,000 | -30.4% | 622,548 | -14.7% | 0.38% | -22.3% |
| Q3 2018 | $13,504,000 | -19.1% | 729,948 | 0.0% | 0.48% | -17.4% |
| Q2 2018 | $16,687,000 | -22.1% | 729,948 | -3.1% | 0.59% | -21.1% |
| Q1 2018 | $21,432,000 | +34.8% | 753,322 | 0.0% | 0.74% | +18.7% |
| Q4 2017 | $15,903,000 | +15.6% | 753,322 | -0.5% | 0.63% | +1.1% |
| Q3 2017 | $13,751,000 | +17.2% | 756,822 | 0.0% | 0.62% | -1.1% |
| Q2 2017 | $11,731,000 | -28.0% | 756,822 | -19.8% | 0.63% | -0.3% |
| Q1 2017 | $16,293,000 | +57.1% | 943,433 | 0.0% | 0.63% | +47.1% |
| Q4 2016 | $10,368,000 | -29.9% | 943,433 | 0.0% | 0.43% | -37.9% |
| Q3 2016 | $14,793,000 | +53.5% | 943,433 | 0.0% | 0.69% | +81.5% |
| Q2 2016 | $9,637,000 | -20.8% | 943,433 | 0.0% | 0.38% | -26.8% |
| Q1 2016 | $12,170,000 | -38.4% | 943,433 | -0.3% | 0.52% | -35.2% |
| Q4 2015 | $19,743,000 | – | 946,022 | – | 0.80% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,500,000 | $7,635,000 | 1.78% |
| Altium Capital Management LP | 1,233,642 | $6,279,000 | 1.65% |
| RA Capital Management | 3,500,000 | $17,815,000 | 0.25% |
| Soleus Capital Management, L.P. | 261,050 | $1,329,000 | 0.21% |
| Affinity Asset Advisors, LLC | 125,000 | $636,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,078,103 | $5,488,000 | 0.16% |
| Point72 Asset Management, L.P. | 6,303,025 | $32,082,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 249,146 | $1,268,000 | 0.13% |
| Candriam S.C.A. | 3,305,940 | $16,826,000 | 0.11% |
| RTW INVESTMENTS, LP | 1,400,939 | $7,131,000 | 0.11% |